Takeda Pharmaceutical (TKPHF) EBITDA (2017 - 2026)

Takeda Pharmaceutical's EBITDA history runs 10 years deep, the most recent figure standing at -$86.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 103.47% year-over-year to -$86.9 million; the TTM figure through Mar 2026 stood at $10.4 billion (down 10.24% YoY), while the FY2026 annual figure was $2.7 billion, up 20.74% from the prior year.
• EBITDA was -$86.9 million for Q1 2026 at Takeda Pharmaceutical, down from $1.3 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.8 billion in Q3 2025 to a low of -$86.9 million in Q1 2026.
• Historically, EBITDA has averaged $2.0 billion across 5 years, with a median of $1.3 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 105.33% in 2024, then jumped 3788.09% in 2025.
• A 5-year view of EBITDA shows it stood at $1.0 billion in 2022, then surged by 51.96% to $1.6 billion in 2023, then declined by 21.24% to $1.2 billion in 2024, then climbed by 4.84% to $1.3 billion in 2025, then slumped by 106.65% to -$86.9 million in 2026.
• The last three EBITDA figures came in at -$86.9 million (Q1 2026), $1.3 billion (Q4 2025), and $6.8 billion (Q3 2025), per Business Quant data.